High‐Titer Antinuclear Antibody Defines a Distinct IgG4‐Related Disease Subset With Predilection for Lung and Kidney Involvement
Journal of Immunology Research · 2026-01 · 2026 (1)
DOI: 10.1155/jimr/5243624 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Immunology Research, online erschienen am 30.10.2026. Verfasst von Jie Zhang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology and Immunology, The First Medical Center of Chinese PLA General Hospital, 28 Fuxing Road, Haidian District, Beijing, 10085…. Hauptthemen laut MEDLINE: Antibodies, Antinuclear, Immunoglobulin G4-Related Disease, Immunoglobulin G, Lung. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Beijing Municipality, Chinese PLA General Hospital Fourth Medical Center Independent Innovation Science Fund.
Abstract (Originalsprache)
Objective
This study investigated whether antinuclear antibody (ANA) positivity identifies a distinct clinical phenotype in IgG4‐related disease (IgG4‐RD), characterized by specific organ involvement patterns.
Methods
We conducted a cohort study of patients diagnosed with IgG4‐RD (2016–2024). Based on indirect immunofluorescence (IIF) results, patients were categorized as ANA‐negative (titer ≤ 1:100) or ANA‐positive, with the latter further stratified by titer: group 1 (moderate titer, 1:320) and group 2 (high titer, ≥1:1000). We comprehensively compared demographics, organ involvement, and laboratory profiles across groups. Multivariable logistic regression was used to quantify associations.
Results
Among 278 patients, 38 (13.7%) were ANA‐positive ( n = 19 per titer‐based subgroup). ANA patterns differed: granular in group 1 versus homogeneous/granular homogeneous in group 2. Only patients in group 2 (high‐titer ANA) demonstrated a significantly elevated risk of lung and kidney initial onset and involvement compared to ANA‐negative patients. This group also exhibited marked hypocomplementemia. The adjusted odds ratios for lung and kidney involvement in group 2 were 10.18 (95% CI: 3.590–28.876) and 4.42 (95% CI: 1.605–12.151), respectively. No such associations were found in group 1.
Conclusion
IgG4‐RD combined with high‐titer ANA (≥1:1000), mainly presenting as homogeneous type or homogeneous granular type, characterized by a heightened propensity for lung and kidney, initial onset and involvement, and hypocomplementemia. Routine ANA testing and careful assessment of pulmonary and renal systems are warranted in these patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Rheumatology and Immunology, The First Medical Center of Chinese PLA General Hospital, 28 Fuxing Road, Haidian District, Beijing, 100853, China, 301hospital.com.cn.
ORCID-Profile: Jie Zhang, Yurong Zhao, Yiwen Wang, Chao Xue, Lidong Hu, Jianglin Zhang, Jian Zhu
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Beijing Municipality
- Chinese PLA General Hospital Fourth Medical Center Independent Innovation Science Fund
Zitieren
APA
Zhang, J., Zhao, Y., Wang, Y., Xue, C., Hu, L., Zhang, J., & Zhu, J. (2026). High‐Titer Antinuclear Antibody Defines a Distinct IgG4‐Related Disease Subset With Predilection for Lung and Kidney Involvement. Journal of Immunology Research, 2026(1). https://doi.org/10.1155/jimr/5243624
Vancouver
Zhang J, Zhao Y, Wang Y, Xue C, Hu L, Zhang J, et al. High‐Titer Antinuclear Antibody Defines a Distinct IgG4‐Related Disease Subset With Predilection for Lung and Kidney Involvement. Journal of Immunology Research. 2026;2026(1). doi:10.1155/jimr/5243624
BibTeX
@article{Zhang2026,
author = {Zhang, Jie and Zhao, Yurong and Wang, Yiwen and Xue, Chao and Hu, Lidong and Zhang, Jianglin and Zhu, Jian},
title = {High‐Titer Antinuclear Antibody Defines a Distinct IgG4‐Related Disease Subset With Predilection for Lung and Kidney Involvement},
journal = {Journal of Immunology Research},
year = {2026},
volume = {2026},
number = {1},
doi = {10.1155/jimr/5243624}
}
EUVIMED